

AroCells new Board of Directors proposed for the Annual General Meeting 2022

The Nomination Committee proposes two new board members to AroCells Board of Directors at the 2022 Annual General Meeting through new election of Johan Häggblad and Agneta Tufvesson Alm.

Johan Häggblad has more than 30 years of experience in the pharmaceutical industry in managerial and executive roles. Johan is Chief Scientific Officer at Calliditas. Prior to that, he served as CEO of Pharmalink between 2007 and 2017. His previous management positions were at NeuroNova, Pharmacia Corporation, and Karo Bio AB. Johan has a PhD in neurochemistry and neurotoxicology from Stockholm University and did his postdoc in pharmacology and physiology at New York University and the University of Oxford.

Agneta Tufvesson Alm has more than 30 years of experience in international sales and marketing as well as experience in direct sales in the Nordic countries and the United Kingdom, region and key account management in Europe, Africa, and the Middle East. Agneta has worked with building distribution networks, contract negotiations, management of sales and customer service teams. She currently works at Kemira Kemi AB and has previously held roles at HemoCue AB, Thermo Quest, and Kabi Pharmacia, among others. Agneta has a bachelor's degree in chemistry from Lund University.

The new proposal for the board that proposes the AGM is: Re-election of Eva Nordström, Charlotta Ljungqvist, and Max Pihlqvist, and the new election of Agneta Tufvesson Alm and Johan Häggblad.

The Nomination Committee proposes the new election of Johan Häggblad as the Chairman of the Board.

AroCells Nomination Committee consists of:

Jon Eiken (Chairman)

Mikael Lönn

Clas Runnberg

Contacts

Anders Hultman, CEO

Phone: +46(0)18 50 30 20

E-mail: anders.hultman@arocell.com

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare and established in various markets. In oncology, AroCell uses various biomarkers, TK1 and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90. For more information; www.arocell.com

Attachments

[AroCells new Board of Directors proposed for the Annual General Meeting 2022](#)